The Medicines and Healthcare products Regulatory Agency (MHRA) has issued an alert via the Central Alerting System (CAS). This gives details about the recent announcement of the interim results from the National Institute for Health Research (NIHR) supported PRINCIPLE trial shows that inhaled budesonide (typically used and licensed in the management of asthma) can reduce the recovery time for COVID-19 positive patients being managed within primary care. This is the first COVID-19 treatment for use in the UK within a community setting.
Details of the CAS alert can be found here.
The Interim Position Statement: Inhaled budesonide for adults (50 years and over) with COVID-19 can be viewed here.
The CEM/CMO therapeutic alert can be viewed here.